A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B.
Status:
Completed
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and safety of PEGASYS (peginterferon alfa-2a) in
patients with HBeAg positive chronic hepatitis B. Patients will be stratified into group A
(treatment naïve patients) or B (YMDD mutant patients). All patients will receive PEGASYS 180
micrograms subcutaneously once weekly for 48 weeks, followed by 24 weeks of treatment-free
follow up.